N-(4-环己基苯基)硫脲 | 175205-17-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-环己基苯基)硫脲
• 中文别名: 4-环己基苯硫脲
• 英文名称: 1-(4-cyclohexylphenyl)thiourea
• 英文别名: 4-cyclohexylphenylthiourea；(4-cyclohexylphenyl)thiourea
• CAS: 175205-17-1
• 化学式: C₁₃H₁₈N₂S
• 分子量: 234.365
• InChiKey: NUOXMWHYKUBMNI-UHFFFAOYSA-N

物化性质

• 沸点：
  372.7±35.0 °C(Predicted)
• 密度：
  1.179±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  70.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(4-环己基苯基)硫脲 在 三甲基铝 、 氯化铵 作用下， 以 丙酮 、 甲苯 为溶剂， 生成 4-{2-[(4-cyclohexylphenyl)amino](1,3-thiazol-4-yl)}-5-methylthiothiophene-2-carboxamidine
  参考文献：
  名称：

  Synthesis of thiophene-2-carboxamidines containing 2-amino-thiazoles and their biological evaluation as urokinase inhibitors

  摘要：

  The serine protease urokinase (uPa) has been implicated in the progression of both breast and prostate cancer. Utilizing structure based design, the synthesis of a series of substituted 4-[2-amino- 1,3-thiazolyl]-thiophene-2-carboxamidine is described. Further optimization of this series by substitution of the terminal amine yielded urokinase inhibitors with excellent activities. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00102-0
• 作为产物：
  描述：

  1-Benzoyl-3-(4-cyclohexyl-phenyl)-thiourea 在 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 N-(4-环己基苯基)硫脲
  参考文献：
  名称：

  取代的N-苯基异硫脲：具有神经元同工型选择性的人一氧化氮合酶的有效抑制剂。

  摘要：

  已经发现S-乙基N-苯基异硫脲（4）是一氧化氮合酶的人组成型和诱导型同工型的有效抑制剂。合成了一系列取代的N-苯基异硫脲类似物，以研究这类抑制剂的构效关系。评价每种类似物的人同工型选择性。一种类似物S-乙基N- [4-（三氟甲基）苯基]异硫脲（39）对神经元同工型的诱导选择性和对内皮衍生的组成型同工型的选择性分别为115倍和29倍。研究表明，取代的N-苯基异硫脲39与L-精氨酸竞争性结合。

  DOI：

  10.1021/jm960785c

文献信息

• Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US06291514B1

  公开（公告）日：2001-09-18

  The present invention is directed to compounds of Formula I: wherein X is O, S or NR7 and R1-R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.

  本发明涉及以下式的化合物： 其中X为O、S或NR7，R1-R7、Y和Z如规范中所述，并且其水合物、溶剂合物或药用可接受的盐也被描述。还描述了制备上述式化合物的方法。本发明的新化合物是蛋白酶的有效抑制剂，特别是胰蛋白酶样丝氨酸蛋白酶，如凝血酶、胰蛋白酶、纤溶酶和尿激酶。其中某些化合物表现出对尿激酶的直接、选择性抑制，或者是用于形成具有这种活性的化合物的中间体。
• Compounds and compositons for treating C1s-mediated diseases and conditions
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20020037915A1

  公开（公告）日：2002-03-28

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3 , R 4 , X, Y and Z are defined in the specification.

  揭示了一种治疗急性或慢性疾病症状的方法，该疾病是由补体级联的经典途径介导的，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4、X、Y和Z。
• Rapid assembly of 2-aminoimidazolones on solid support
  作者：Kexin Yang、Boliang Lou、Hossain Saneii

  DOI：10.1016/s0040-4039(02)00828-6

  日期：2002.6

  straightforward solid-phase synthesis of 2-aminoimidazolone derivatives is described. The synthesis starts with immobilization of thioureas onto solid support, followed by HBTU/DIEA assisted coupling of Boc-protected amino acids. Upon removal of the Boc group, intramolecular cyclization and simultaneous cleavage are promoted by polyamine resin to give the 2-aminoimidazolone derivatives in good yields and excellent

  描述了2-氨基咪唑酮衍生物的直接固相合成。合成开始于将硫脲固定在固体支持物上，然后由HBTU / DIEA辅助Boc保护的氨基酸偶联。除去Boc基团后，聚胺树脂促进了分子内环化和同时裂解，从而以良好的收率和优异的纯度得到了2-氨基咪唑啉酮衍生物。
• Substituted arylthiourea derivatives useful as inhibitors of viral replication
  申请人：Phadke Avinash

  公开号：US20050032849A1

  公开（公告）日：2005-02-10

  Substituted arylthiourea compounds of Formula I, and the pharmaceutically acceptable salts of such compounds, useful as antiviral agents, are provided herein. Certain substituted arylthioureas disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions containing one or more substituted arylthiourea compounds and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Such pharmaceutical compositions may contain a substituted arylthiourea as the only active agent or may contain a combination of a substituted arylthiourea derivative and one or more other pharmaceutically active agents. Methods of treating Hepatitis C viral infections in mammals are also provided herein.

  本文提供了化合物I的取代芳基硫脲化合物及其药学上可接受的盐，可用作抗病毒剂。本文披露的某些取代芳基硫脲具有强效和/或选择性抑制病毒复制的能力，特别是丙型肝炎病毒复制。本文还提供了含有一种或多种取代芳基硫脲化合物和一种或多种药学上可接受的载体、赋形剂或稀释剂的制药组合物。这种制药组合物可以仅包含一种取代芳基硫脲作为唯一活性剂，也可以包含一种取代芳基硫脲衍生物和一种或多种其他药学活性剂的组合。本文还提供了治疗哺乳动物丙型肝炎病毒感染的方法。
• Methods of treating C1s-mediated diseases and conditions and compositions thereof
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US06492403B1

  公开（公告）日：2002-12-10

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, X, Y and Z are defined in the specification.

  本发明涉及一种治疗由补体级联经典途径介导的急性或慢性疾病症状的方法，包括向需要此类治疗的哺乳动物中投与化合物I的治疗有效量或其溶剂、水合物或药学上可接受的盐；其中R1、R2、R3、R4、X、Y和Z在规范中定义。